Nutex Health Inc. (NASDAQ:NUTX), a physician-led healthcare services and operations company, began trading publicly through a reverse merger in April 2022. The company is set to release its quarterly earnings on Tuesday, August 26, 2025, after market close. Wall Street estimates the earnings per share to be a loss of $5.43, with projected revenue of approximately $186.7 million.
A class action lawsuit has been filed against Nutex Health, targeting those who purchased or acquired its securities between August 8, 2024, and August 14, 2025. As highlighted by Robbins LLP, this legal action could significantly impact the company's stockholders and market performance. The lawsuit adds a layer of uncertainty to the upcoming earnings release.
Nutex Health recently held its Q2 2025 earnings conference call on August 25, 2025. Key participants included Jon C. Bates, the Chief Financial Officer, and Michael Chang, the Chief Medical Officer. The call provided insights into the company's financial performance and strategic initiatives, offering a glimpse into its operations and future outlook.
The price-to-sales ratio stands at about 0.80, suggesting the stock is trading at a low price relative to its sales. The company's enterprise value to sales ratio is approximately 1.21, reflecting its valuation in relation to revenue. With an enterprise value to operating cash flow ratio of around 10.61, the market values Nutex Health's cash flow favorably. The debt-to-equity ratio is about 1.73, indicating a moderate level of debt compared to equity, while a current ratio of approximately 2.27 suggests a strong ability to cover short-term liabilities.
